Chemgenex gets milestone from Vernalis
Wednesday, 23 February, 2005
Chemgenex Pharmaceuticals (ASX:CXS) will receive a AUD$720,000 milestone payment from its partner Vernalis for progress made on its depression and anxiety target discovery program.
The companies entered into a partnership agreement in August last year, which is worth as much as $2 million in the first year depending on the achievement of milestones, and are working on a further licensing and collaboration agreement. To date, the company has identified ten novel genes and proteins associated with depression and anxiety.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
